Suryaa Now Business News Desk: Pharmaceutical company Eli Lilly has announced successful results from the third phase of clinical trials for its new weight management and obesity prevention medication. According to the company, patients who participated in the trials experienced significant weight loss.
The trial reports indicate that, in addition to weight reduction, the medication helped lower the risks associated with obesity, including heart disease and diabetes. Following the announcement of these results, Eli Lilly shares have seen an increase. The company stated that it is working to expedite the regulatory approval process to make the medication available in the market.
